Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Core Viewpoint - Mesoblast Limited, a leader in allogeneic cellular medicines for inflammatory diseases, provided a trading update and operational overview during the Chief Executive's Annual General Meeting, highlighting significant revenue growth and ongoing development of its therapies [1][2]. Financial Performance - For the quarter ending December 31, 2025, Mesoblast expects gross revenue exceeding US$30.0 million from Ryoncil® sales, marking a more than 37% increase from US$21.9 million in the previous quarter [2]. Product Overview - Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [4]. - The company is also developing Ryoncil® for additional inflammatory diseases, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while rexlemestrocel-L is being developed for heart failure and chronic low back pain [5]. Intellectual Property - Mesoblast holds a robust global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection extending to at least 2044 in major markets [6]. Manufacturing Capabilities - The company utilizes proprietary manufacturing processes to produce industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [7]. Global Presence - Mesoblast operates in Australia, the United States, and Singapore, and is listed on both the Australian Securities Exchange (MSB) and Nasdaq (MESO) [8].